MorphoSys Nabs GSK As Latest Partner For RA Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
The British pharma is expanding its portfolio in rheumatoid arthritis through a mid-stage tie-up with German biotech MorphoSys. GSK will take over all development of the antibody and could pay milestones up to €425 million.